Intra-coronary Hyperoxemic Therapy — CPB 0801 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0801 covering intra-coronary hyperoxemic therapy, effective December 4, 2025. Every indication under this policy is classified as experimental, investigational, or unproven — meaning no reimbursement for Aetna members, full stop.

If your cardiology or neurology billing team submits claims for hyperoxemic reperfusion therapy, aqueous oxygen therapy, or super-saturated oxygen infusion, this Aetna intra-coronary hyperoxemic therapy coverage policy gives you one answer across the board: denied. Here's what your team needs to know before that denial hits.

Quick-Reference Table

Aetna Intra-Coronary Hyperoxemic Therapy Coverage Criteria and Medical Necessity Requirements 2025

The short version: there are no coverage criteria to meet. Aetna's coverage policy under CPB 0801 classifies intra-coronary hyperoxemic therapy as experimental, investigational, or unproven for every listed indication. Medical necessity cannot be established for any of them under this policy.

This matters because "experimental or investigational" is not the same as "non-covered for administrative reasons." It means Aetna has reviewed the clinical evidence and concluded it does not support coverage. That classification holds regardless of what your referring physician documents, what the treating cardiologist argues on appeal, or how compelling the patient's case looks.

Prior authorization won't save these claims either. When a payer classifies a therapy as experimental under a clinical policy bulletin, prior auth is typically unavailable — you can't get approval for something the payer has already ruled out on clinical grounds. If your team has been trying to get prior authorization for aqueous oxygen therapy or super-oxygenated reperfusion on Aetna plans, stop. The policy forecloses that path.

The billing guidelines here are straightforward but important: do not submit claims expecting coverage. If a provider performs this therapy on an Aetna member and bills for it, expect a claim denial citing the experimental designation under CPB 0801.

Aetna Intra-Coronary Hyperoxemic Therapy Exclusions and Non-Covered Indications

This is the core of CPB 0801. Aetna treats every current clinical use of intra-coronary hyperoxemic therapy as experimental, investigational, or unproven. The policy covers multiple names for the same underlying intervention — because this therapy goes by several aliases in clinical and billing documentation, and Aetna is closing every door.

The therapy is also called:

If any of those terms appear in your charge capture, operative notes, or claim descriptions — and the payer is Aetna — you're looking at a denial under this coverage policy.

The five non-covered indications listed in CPB 0801 span a wide range of acute and critical care scenarios. Each one is explicitly named as lacking sufficient evidence for coverage.

Carbon monoxide poisoning. This is coded using T58-range ICD-10 codes (T58.01X+ through T58.94X+) and environmental exposure codes like X00.1XX+ and X02.1XX+. The therapy has been explored as an alternative oxygen delivery method in CO poisoning, but Aetna does not consider the evidence sufficient.

Cardiogenic shock. Coded as R57.0. This is arguably the most financially significant exclusion for interventional cardiology teams. Patients in cardiogenic shock are high-acuity, and the temptation to try newer perfusion strategies is real. Aetna won't cover it.

Radio-contrast nephropathy. Coded across N04.0–N05.9 and N07.0–N07.9, with T50.8X5+ for adverse effects of diagnostic agents. Nephrology teams sometimes encounter hyperoxemic therapy proposals for contrast-induced kidney injury. Not covered.

Reperfusion microvascular ischemia in acute myocardial infarction. This is the indication most directly tied to the "intra-coronary" name. ICD-10 codes I21.01 through I22.9 cover STEMI and NSTEMI presentations. For post-PCI microvascular reperfusion failure, Aetna's answer is no.

Stroke. Coded across the G45 and I60–I69 ranges, plus the I97.810–I97.821 series for intraoperative or postprocedural cerebrovascular infarction. This is the broadest category in the policy and covers transient ischemic attacks, cerebrovascular disease, and procedure-related strokes.

The real issue here is breadth. This isn't a policy that covers some presentations of a therapy and excludes others. It covers nothing. That uniform "experimental" designation means your billing team should treat any hyperoxemic therapy claim against an Aetna plan as a write-off risk before the claim ever goes out.

Coverage Indications at a Glance

Aetna Intra-coronary Hyperoxemic Therapy Billing Guidelines and Action Items 2025

The effective date is December 4, 2025. Here's what your team does now.

If your facility performs hyperoxemic therapy in a clinical trial context, loop in your compliance officer before billing. Research-context billing has different rules, and you don't want a clean trial claim tangled up in a standard coverage denial.

CPT, HCPCS, and ICD-10 Codes for Intra-coronary Hyperoxemic Therapy Under CPB 0801

The CPB 0801 policy document does not list specific CPT or HCPCS procedure codes. This is common for therapies classified as experimental — Aetna effectively blocks coverage at the indication level, so no procedure code combination produces a covered claim. Your billing team should apply the diagnosis codes below as denial flags, not coverage triggers.

Key ICD-10-CM Diagnosis Codes